This Plain Language Summary of Publication article (PLSP) from Future Oncology examines the effectiveness of loncastuximab tesirine (Lonca) in diffuse large B-cell lymphoma patients whose disease progressed after CAR-T therapy. Researchers analyzed medical records of 118 adults who received Lonca following CAR-T treatment failure, dividing patients into two groups based on treatment timing: those who received CAR-T as second-line therapy followed by Lonca as third-line treatment (earlier in their treatment journey), and those who received CAR-T as third-line therapy followed by Lonca as fourth-line treatment (later in their treatment journey).

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma’ and was published in the Blood Cancer Journal.

Visit Nature using the link to read the original article.